Tags

Type your tag names separated by a space and hit enter

A retrospective observational study of the treatment of a nosocomial infection caused by oseltamivir-resistant influenza virus A with baloxavir marboxil.
Respir Investig. 2020 Sep; 58(5):403-408.RI

Abstract

BACKGROUND

Nosocomial (hospital-acquired) influenza A virus infection is a very important clinical issue. The objective of this study is to describe the effect of baloxavir marboxil in controlling an outbreak of this infection.

METHODS

A retrospective observational study was performed to assess the effectiveness of baloxavir marboxil in the treatment of nosocomial infections caused by oseltamivir-resistant influenza virus A.

RESULTS

In September 2019, there was an outbreak of nosocomial influenza A(H1N1)pdm09 viral infection in one out of three facility wards for inpatients at the Okinawa Nanbu Regional Center for Children with Special Needs. Symptomatic staff members were kept off duty until they remained afebrile for 2 days. Prophylactic oseltamivir was administered to inpatients (n = 37) and to staff members (n = 16) who voluntarily requested the drug. However, both inpatients and staff members showed influenza A infection during prophylactic use of oseltamivir. The A(H1N1)pdm09 virus sample obtained from one patient was shown to be oseltamivir-resistant. After administration of baloxavir marboxil, the nosocomial outbreak gradually ceased. Moreover, the time (hours) to alleviation of fever in the oseltamivir group (n = 11) and baloxavir marboxil group (n = 13) was significantly different (p = 0.0034).

CONCLUSION

Our report provides evidence for the usefulness of baloxavir marboxil in treating influenza A patients who have received prophylactic doses of oseltamivir. This is the first report describing the successful use of baloxavir marboxil for of a nosocomial outbreak caused by oseltamivir-resistant influenza A virus.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Fujita M
Okinawa Nanbu Regional Center for Children with Special Needs, Okinawa, Japan.
Matsumoto H
Okinawa Nanbu Regional Center for Children with Special Needs, Okinawa, Japan.
Inafuku Y
Okinawa Nanbu Regional Center for Children with Special Needs, Okinawa, Japan.
Toyama J
Okinawa Nanbu Regional Center for Children with Special Needs, Okinawa, Japan.
Fujita J
Department of Infectious, Respiratory, and Digestive Medicine, Control and Prevention of Infectious Diseases, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan. Electronic address: fujita@med.u-ryukyu.ac.jp.

MeSH

Cross InfectionDibenzothiepinsDisease OutbreaksDrug Resistance, ViralFemaleHumansInfluenza A Virus, H1N1 SubtypeInfluenza, HumanJapanMaleMorpholinesOseltamivirOxazinesPre-Exposure ProphylaxisPyridinesPyridonesRetrospective StudiesThiepinsTreatment OutcomeTriazines

Pub Type(s)

Journal Article
Observational Study

Language

eng

PubMed ID

32605828

Citation

Fujita, Miyako, et al. "A Retrospective Observational Study of the Treatment of a Nosocomial Infection Caused By Oseltamivir-resistant Influenza Virus a With Baloxavir Marboxil." Respiratory Investigation, vol. 58, no. 5, 2020, pp. 403-408.
Fujita M, Matsumoto H, Inafuku Y, et al. A retrospective observational study of the treatment of a nosocomial infection caused by oseltamivir-resistant influenza virus A with baloxavir marboxil. Respir Investig. 2020;58(5):403-408.
Fujita, M., Matsumoto, H., Inafuku, Y., Toyama, J., & Fujita, J. (2020). A retrospective observational study of the treatment of a nosocomial infection caused by oseltamivir-resistant influenza virus A with baloxavir marboxil. Respiratory Investigation, 58(5), 403-408. https://doi.org/10.1016/j.resinv.2020.05.002
Fujita M, et al. A Retrospective Observational Study of the Treatment of a Nosocomial Infection Caused By Oseltamivir-resistant Influenza Virus a With Baloxavir Marboxil. Respir Investig. 2020;58(5):403-408. PubMed PMID: 32605828.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A retrospective observational study of the treatment of a nosocomial infection caused by oseltamivir-resistant influenza virus A with baloxavir marboxil. AU - Fujita,Miyako, AU - Matsumoto,Hirotsugu, AU - Inafuku,Yasuo, AU - Toyama,Jun, AU - Fujita,Jiro, Y1 - 2020/06/27/ PY - 2020/02/18/received PY - 2020/05/01/revised PY - 2020/05/10/accepted PY - 2020/7/2/pubmed PY - 2020/10/28/medline PY - 2020/7/2/entrez KW - Baloxavir marboxil KW - Influenza virus A KW - Nosocomial infection KW - Oseltamivir SP - 403 EP - 408 JF - Respiratory investigation JO - Respir Investig VL - 58 IS - 5 N2 - BACKGROUND: Nosocomial (hospital-acquired) influenza A virus infection is a very important clinical issue. The objective of this study is to describe the effect of baloxavir marboxil in controlling an outbreak of this infection. METHODS: A retrospective observational study was performed to assess the effectiveness of baloxavir marboxil in the treatment of nosocomial infections caused by oseltamivir-resistant influenza virus A. RESULTS: In September 2019, there was an outbreak of nosocomial influenza A(H1N1)pdm09 viral infection in one out of three facility wards for inpatients at the Okinawa Nanbu Regional Center for Children with Special Needs. Symptomatic staff members were kept off duty until they remained afebrile for 2 days. Prophylactic oseltamivir was administered to inpatients (n = 37) and to staff members (n = 16) who voluntarily requested the drug. However, both inpatients and staff members showed influenza A infection during prophylactic use of oseltamivir. The A(H1N1)pdm09 virus sample obtained from one patient was shown to be oseltamivir-resistant. After administration of baloxavir marboxil, the nosocomial outbreak gradually ceased. Moreover, the time (hours) to alleviation of fever in the oseltamivir group (n = 11) and baloxavir marboxil group (n = 13) was significantly different (p = 0.0034). CONCLUSION: Our report provides evidence for the usefulness of baloxavir marboxil in treating influenza A patients who have received prophylactic doses of oseltamivir. This is the first report describing the successful use of baloxavir marboxil for of a nosocomial outbreak caused by oseltamivir-resistant influenza A virus. SN - 2212-5353 UR - https://www.unboundmedicine.com/medline/citation/32605828/A_retrospective_observational_study_of_the_treatment_of_a_nosocomial_infection_caused_by_oseltamivir_resistant_influenza_virus_A_with_baloxavir_marboxil_ DB - PRIME DP - Unbound Medicine ER -